<div class="article">
	<h3>Corrections & Amplifications</h3>
	<div class="article-info">
		<ul>
			<li>Author: null</li>
			<li>Date: 08/09/90</li>
		</ul>
	</div>
	<p class="article-leader">MERCK & Co. has proposed a plan for drugs sold to Medicaid
with price discounts of 10% to 15% in the first two years and
10% to 25% in the fifth year, and the discounts would be
granted by all drug companies, not just Merck. The details of
the Merck plan were misstated in yesterday's edition.
   (See: "Medicine: Drug Concerns Seek to Block Medicaid
Curbs" -- WSJ Aug. 8, 1990)</p>
	<div class="article-body"><p>---</p>
<p>A SYNTRO CORP. EXECUTIVE, clarifying statements he made in
yesterday's edition, said the company expects to be operating
at a break-even level Sept. 30, the end of its fiscal year,
but still expects to report a net loss for the year. Further,
he said the company has a 40% share of the U.S. market for
its swine vaccine. Also, the company had a $1.6 million loss
for the nine months ended June 30. The amount of the loss was
misstated in yesterday's edition.</p>
<p>(See: "Business Brief -- Syntro Corp.: Firm, Upjohn Settle
Suits on Swine Vaccine Patents" -- WSJ Aug. 8, 1990)</p>
<p></p></div>
</div>
